000			03932nam a22005417a 4500
008			210607s20212021 xxu||||| |||| 00| 0 eng d
022			_a2405-500X
024			_a10.1016/j.jacep.2020.09.008 [doi]
024			_aS2405-500X(20)30852-5 [pii]
040			_aOvid MEDLINE(R)
099			_a33358671
245			_aIncidence of Cardiac Implantable Electronic Device Complications in Patients With Left Ventricular Assist Devices.
251			_aJACC. Clinical Electrophysiology. 7(4):494-501, 2021 04.
252			_aJACC Clin Electrophysiol. 7(4):494-501, 2021 04.
252			_zJACC Clin Electrophysiol. 7(4):494-501, 2021 Apr.
253			_aJACC. Clinical electrophysiology
260			_c2021
260			_fFY2021
265			_sppublish
266			_d2020-12-31
268			_aJACC. Clinical Electrophysiology. 7(4):494-501, 2021 Apr.
520			_aBACKGROUND: Patients with LVADs are predisposed to ventricular arrhythmias and frequently have CIEDs before receiving their LVAD. However, the role of CIED procedures such as generator changes (GC) are unclear in this population, given the potential complications of bleeding and infection.
520			_aCONCLUSIONS: In this large, multicenter cohort, we report the incidence of complications for CIED procedures in the LVAD population; specifically, LVAD patients are at increased risk of pocket hematomas, without downstream risk of infection, and do experience a high rate of appropriate device therapies. Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
520			_aMETHODS: This was a retrospective, multicenter study from January 1, 2012, to September 30, 2018. All patients with LVADs were screened and those who had a CIED GC, implantation, or revision were included in the study and followed until December 31, 2018.
520			_aOBJECTIVES: The objective of this study was to describe the risk of cardiac implantable electronic devices (CIEDs) complications in patients with left ventricular assist devices (LVADs).
520			_aRESULTS: A total of 179 patients across 6 centers had a CIED procedure after LVAD implantation. The mean age was 59.5 +/- 13.4, with the cohort comprising mostly men (78%), destination LVAD therapy (53.8%), and GC (66%). The 30-day primary composite endpoint of hematoma or device infection occurred in 34 (19%) patients. The secondary endpoints of rehospitalization within 30 days and appropriate device therapy during follow-up occurred in 40 (22%) and 42 (24%) patients respectively. Of the 126 patients without previous device therapy, 14.3% received appropriate therapy during follow-up.
546			_aEnglish
650			_a*Heart Failure
650			_a*Heart-Assist Devices
650			_aElectronics
650			_aHeart Failure/ep [Epidemiology]
650			_aHeart-Assist Devices/ae [Adverse Effects]
650			_aHumans
650			_aIncidence
650			_aMale
650			_aMiddle Aged
650			_aRetrospective Studies
651			_aMedStar Heart & Vascular Institute
651			_aMedStar Washington Hospital Center
656			_aInternal Medicine Residency
657			_aJournal Article
700			_aAhmed, Sara
700			_aSheikh, Farooq
790			_aAhmed S, Bauza K, Cantillon DJ, D'Souza B, Gilge JL, Herr J, Hsiao S, Khedraki R, Patel PJ, Ravichandran AK, Sbircea N, Sheikh FH, Srivastava A, Tong MZ
856			_uhttps://dx.doi.org/10.1016/j.jacep.2020.09.008 _zhttps://dx.doi.org/10.1016/j.jacep.2020.09.008 _zhttps://dx.doi.org/10.1016/j.jacep.2020.09.008xl - https://dx.doi.org/10.1016/j.jacep.2020.09.008
856			_uhttps://dx.doi.org/10.1016/j.jacep.2020.09.008xl - https://dx.doi.org/10.1016/j.jacep.2020.09.008 _zhttps://dx.doi.org/10.1016/j.jacep.2020.09.008 _zhttps://dx.doi.org/10.1016/j.jacep.2020.09.008xl - https://dx.doi.org/10.1016/j.jacep.2020.09.008
942			_cART _dArticle
999			_c5923 _d5923